MAX Chat
Company Analysis Evolent Health
1. Summary
Advantages
- Price (8.8 $) is less than fair price (11.38 $)
- The company's current efficiency (ROE=-5.96%) is higher than the sector average (ROE=-73.65%)
Disadvantages
- Dividends (0%) are below the sector average (1.3%).
- The stock's return over the last year (-26.36%) is lower than the sector average (-16.76%).
- Current debt level 28.05% has increased over 5 years from 24.59%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Evolent Health | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.2% | -8.6% | -0.5% |
| 90 days | 3.8% | -11% | 8% |
| 1 year | -26.4% | -16.8% | 14.6% |
EVH vs Sector: Evolent Health has significantly underperformed the "Healthcare" sector by -9.6% over the past year.
EVH vs Market: Evolent Health has significantly underperformed the market by -40.99% over the past year.
Stable price: EVH is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EVH with weekly volatility of -0.5069% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (8.8 $) is lower than the fair price (11.38 $).
Price significantly below the fair price: The current price (8.8 $) is 29.3% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (-16.38) is lower than that of the sector as a whole (29.26).
P/E vs Market: The company's P/E (-16.38) is lower than that of the market as a whole (52.32).
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.26) is lower than that of the sector as a whole (10.48).
P/BV vs Market: The company's P/BV (1.26) is lower than that of the market as a whole (18.5).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.4929) is lower than that of the sector as a whole (3.99).
P/S vs Market: The company's P/S indicator (0.4929) is lower than that of the market as a whole (27.95).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (22.02) is higher than that of the sector as a whole (18.36).
EV/Ebitda vs Market: The company's EV/Ebitda (22.02) is lower than that of the market as a whole (37.43).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -16.31% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-16.31%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.3%).
5.4. ROE
ROE vs Sector: The company's ROE (-5.96%) is higher than that of the sector as a whole (-73.65%).
ROE vs Market: The company's ROE (-5.96%) is lower than that of the market as a whole (36.05%).
5.5. ROA
ROA vs Sector: The company's ROA (-2.36%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (-2.36%) is lower than that of the market as a whole (11.45%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-2.2%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (-2.2%) is lower than that of the market as a whole (10.19%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.3%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
